香港股市 已收市

Dr. Reddy's Laboratories Limited (DRREDDY.BO)

BSE - BSE 即時價格。貨幣為 INR。
加入追蹤清單
6,255.75+304.55 (+5.12%)
市場開市。 截至 02:30PM IST。

Dr. Reddy's Laboratories Limited

8-2-337, Road No. 3
Banjara Hills
Hyderabad 500034
India
91 40 4900 2900
https://www.drreddys.com

版塊Healthcare
行業Drug Manufacturers - Specialty & Generic
全職員工25,863

高階主管

名稱頭銜支付行使價出生年份
Mr. Gunupati Venkateswara Prasad B.E.Co-Chairman, MD & Member of Management Council187.71M1960
Mr. Kallam Satish Reddy B.Tech., M.S.Chairman of the Board & Member of the Management Council115.4M1967
Mr. Erez Israeli M.B.A.CEO & Member of the Management Council1968
Mr. Parag AgarwalCFO & Member of Management Council1967
Mr. Deepak Sapra M.B.A.CEO of API & Services & Member of Management Council1975
Mr. Venkata Ramana Motupalli M.B.A.CEO of Branded Markets - India & Emerging Countries and Member of Management Council1969
Ms. Archana Bhaskar B.Sc., M.B.A.EVP, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council1967
Mr. Sanjay Sharma B.Tech.Executive VP, Global Head of Global Manufacturing & Member of Management Council1968
Mr. Marc Kikuchi B.A., M.B.A.CEO of North America Generics & Member of Management Council1969
Mr. Patrick Aghanian B.A., M.B.A.CEO of European Generics & Member of Management Council1965
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 INR。

描述

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

公司管治

截至 2024年4月1日 止,Dr. Reddy's Laboratories Limited 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中:6;董事會:3;股東權利:1;現金賠償:7。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。